0RQO Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 313.08 |
| 52 Week High | SEK 330.80 |
| 52 Week Low | SEK 111.80 |
| Beta | 1.01 |
| 11 Month Change | 6.13% |
| 3 Month Change | 18.95% |
| 1 Year Change | 145.55% |
| 33 Year Change | 694.61% |
| 5 Year Change | n/a |
| Change since IPO | 1,390.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RQO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.0% | 1.3% | -0.5% |
| 1Y | 145.6% | -16.3% | 7.9% |
Return vs Industry: 0RQO exceeded the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0RQO exceeded the UK Market which returned 7.9% over the past year.
Price Volatility
| 0RQO volatility | |
|---|---|
| 0RQO Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0RQO has not had significant price volatility in the past 3 months.
Volatility Over Time: 0RQO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 127 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| 0RQO fundamental statistics | |
|---|---|
| Market cap | SEK 20.39b |
| Earnings (TTM) | SEK 288.78m |
| Revenue (TTM) | SEK 735.16m |
70.6x
P/E Ratio27.7x
P/S RatioIs 0RQO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RQO income statement (TTM) | |
|---|---|
| Revenue | SEK 735.16m |
| Cost of Revenue | SEK 57.19m |
| Gross Profit | SEK 677.97m |
| Other Expenses | SEK 389.19m |
| Earnings | SEK 288.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | 4.39 |
| Gross Margin | 92.22% |
| Net Profit Margin | 39.28% |
| Debt/Equity Ratio | 0% |
How did 0RQO perform over the long term?
See historical performance and comparison